Participating in the corporate presentation session for the first time this year
Introducing four follow-up products set for release in the second half,
Celltrion booth at Bio USA ⓒCelltrion, ‘[Daily Ann = Reporter Lee So-young] Celltrion announced on the 10th that it would participate in the “2025 Bio International Convention” (hereafter referred to as Bio USA), held in Boston, USA, from June 16 to 19 (local time), aiming to strengthen global partnerships.’,
,
, ‘Now in its 32nd year, Bio USA is the world’s largest bio exhibition event, with participation from over 1,800 pharmaceutical and bio companies worldwide. Celltrion has been participating in Bio USA for 16 consecutive years since 2010, showcasing its technological competitiveness and brand in key areas such as biosimilars and new drug development while continuously expanding partnerships.’,
,
, ‘At this event, Celltrion will operate a standalone booth covering about 140 square meters. The company plans to continue meetings with numerous global companies through open meeting spaces and private meeting rooms. Through these efforts, Celltrion aims to identify promising new modality development trends and seek cooperation with potential partners to expand the pipeline of next-generation antibody-drug conjugates (ADC) and antibody new drugs.’,
,
, ‘Additionally, Celltrion plans to promote the competitiveness of its biosimilar products and follow-up pipeline to Bio USA participants and strengthen partnerships in various areas, including global bio-cluster networks and Contract Manufacturing Organizations (CMO) site cooperation.’,
,
, ‘Notably, this year, Celltrion will participate in the corporate presentation session at Bio USA to showcase its unique business capabilities, covering the entire process from the research and development of pharmaceuticals to clinical trials, approval, production, and sales, to industry stakeholders. Moreover, the company will widely introduce its open innovation strategies for new drug development status and promising technology discovery.’,
,
, ‘A Celltrion representative stated, “Based on the thoroughly proven competitiveness of our biosimilar business in the global pharmaceutical market, this year we aim to promote Celltrion’s new business sector as it leaps toward becoming a new drug development company. We will actively explore various promising technologies to expand our new drug pipeline,” adding, “At this year’s Bio USA, we aim to strengthen our global partnerships by discovering potential partners with innovative technologies and expanding open innovation.”‘